Therapeutic anti-PD-1 antibodies can not only block PD-1 on CD8+ T cells to maintain the anti-tumor effect of T cells, but also block PD-1 on ILC2s to indirectly enhance the anti-tumor immunity. This evidence concerns the gene CD8A and neoplasm.